Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIN: COR388 in Alzheimer's Disease
NCT03823404Phase 3Completed
- Sponsor
- IRulya Therapeutics
- Start
- Mar 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of atuzaginstat in Alzheimer's disease (AD), sponsored by IRulya Therapeutics. Started Mar 2019; status: completed.
02
Drugs
atuzaginstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03823404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823404.